Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-HPV 18 [HPV18/1297]: MC0283, MC0283RTU7

Intended Use: For Research Use Only

Description: Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis has shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

Specifications:

Clone:	HPV18/1297
Source:	Mouse
Isotype:	IgG1k
Reactivity:	Type 18 of HPV 18
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and $\leq$ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC

Package:

Description	Catalog No.	Size
HPV 18 Concentrated	MC0283	1 ml
HPV 18 Prediluted	MC0283RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	HPV 18 infected cells or cervical tissue
Concentrated Dilution:	50-200
Pretreatment:	Citrate pH6.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 min @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human cervix stained with anti-HPV18 using DAB

References:

1. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Krishnappa P, et al. Diagn Pathol 9:202, 2014.
2. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Day PM, et al. Clin Vaccine Immunol 19:1075-82, 2012.
3. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Millán AF, et al. Protein Expr Purif 74:1-8, 2010.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 877-524-9167 www.medaysis.com